BRAF

News

Pfizer builds on Braftovi bowel cancer OK with survival data

Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.

News

Novartis bags FDA okay for BRAF-positive tumour combination

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in t

News

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks